CAS: 1228108-65-3; (1R)-1,1',6,6',7,7'-Hexahydroxy-3,3'-Dimethyl-N5,N5'-Bis((2R)-2-Phenylpropyl)-[2,2'-Binaphthalene]-5,5'-Dicarboxamide

结构式图片

物理性质

MSDS等安全信息

上下游产品

5,N5'-bis(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-N5,N5'-bis(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide (rac)-gossypol apogossypol 5,5'-diisopropyl-1,1',6,6',7,7'-hexamethoxy-3,3'-dimethyl-2,2'-binaphthalene5,N5'-bis(2-phenylpropyl)-1,1',4,4'-tetrahydro-2,2'-binaphthyl-5,5'-dicarboxamide6,6',7,7'-tetrahydroxy-3,3'-dimethyl-1,1',4,4'-tetraoxo-N5,N5'-bis(2-phenylpropyl)-1,1',4,4'-tetrahydro-2,2'-binaphthyl-5,5'-dicarboxamide

合成工艺路线路线简述

    专利信息


    专利号:US-2025289827-A1
    优先权日:2022-12-02
    标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
    发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
    权利人:C4 THERAPEUTICS INC
    摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Hu Y, Yagüe E, Zhao J, Wang L, Bai J, Yang Q, Pan T, Zhao H, Liu J, Zhang J. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Lett. 2018 Jun 1;423:47-59. doi: 10.1016/j.canlet.2018.02.036. Epub 2018 Feb 27. 14(7):656-65. doi: 10.1593/neo.12640.
    3: Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D, Cohen GM. Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia. 2013 May;15(5):568-78. doi: 10.1593/neo.13230.
    4: Li C, Song Y, Li P. MCL1 regulates cell death, tumor growth and chemosensitivity to sabutoclax in ovarian adenocarcinoma. Cell Tissue Res. 2020 Mar;379(3):625-633. doi: 10.1007/s00441-019-03105-8. Epub 2019 Nov 21. 39(3):1811-1821. doi: 10.1002/tox.24064. Epub 2023 Dec 10. 32(1):105-112. doi: 10.1080/09537104.2020.1724276. Epub 2020 Feb 21. 108(21):8785-90. doi: 10.1073/pnas.1100769108. Epub 2011 May 9. Erratum in: Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4522-E4523. doi: 10.1073/pnas.1706353114.

    合成参考文献


    参考文献:10.1021/jm1001265
    摘要:Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, Wu B, Cellitti J, Zhai D, Yang L, Dahl R, Fisher PB, Reed JC, Pellecchia M. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem. 2010 May 27;53(10):4166–76.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知